Domestic insulin enters the US market for the first time, Dongyang Sunshine Pharmaceutical's Ganjing insulin receives FDA approval.

The Glargine Insulin Injection under the company has officially received approval from the U.S. FDA for market launch, becoming the fourth Glargine insulin product to be marketed in the U.S. and the first insulin product from China to enter the U.S. market. The product has also been granted an "interchangeable" label, allowing it to directly substitute the original drug Lantus at pharmacies. Currently, East Sunshine Pharmaceuticals has received the first order from their U.S. partner Lannett for Glargine Insulin Injection, with a total order quantity of at least 18 million units over a supply period of 18 months.